CA2329913A1 - Paroxetine 10-camphorsulfonate for treatment of cns disorders - Google Patents
Paroxetine 10-camphorsulfonate for treatment of cns disorders Download PDFInfo
- Publication number
- CA2329913A1 CA2329913A1 CA002329913A CA2329913A CA2329913A1 CA 2329913 A1 CA2329913 A1 CA 2329913A1 CA 002329913 A CA002329913 A CA 002329913A CA 2329913 A CA2329913 A CA 2329913A CA 2329913 A1 CA2329913 A1 CA 2329913A1
- Authority
- CA
- Canada
- Prior art keywords
- paroxetine
- camphorsulfonate
- solution
- salt
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9808894.1A GB9808894D0 (en) | 1998-04-25 | 1998-04-25 | Novel compound |
GB9808894.1 | 1998-04-25 | ||
PCT/GB1999/001246 WO1999055699A1 (en) | 1998-04-25 | 1999-04-23 | Paroxetine 10-camphorsulfonate for treatment of cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2329913A1 true CA2329913A1 (en) | 1999-11-04 |
Family
ID=10831007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002329913A Abandoned CA2329913A1 (en) | 1998-04-25 | 1999-04-23 | Paroxetine 10-camphorsulfonate for treatment of cns disorders |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1076659A1 (xx) |
JP (1) | JP2002513020A (xx) |
KR (1) | KR20010042929A (xx) |
CN (1) | CN1306530A (xx) |
AP (1) | AP2000001958A0 (xx) |
AU (1) | AU3618699A (xx) |
BG (1) | BG104973A (xx) |
BR (1) | BR9909878A (xx) |
CA (1) | CA2329913A1 (xx) |
EA (1) | EA200001105A1 (xx) |
GB (1) | GB9808894D0 (xx) |
HU (1) | HUP0102298A2 (xx) |
IL (1) | IL139018A0 (xx) |
NO (1) | NO20005351L (xx) |
PL (1) | PL343596A1 (xx) |
SK (1) | SK15902000A3 (xx) |
TR (1) | TR200003083T2 (xx) |
WO (1) | WO1999055699A1 (xx) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100672184B1 (ko) | 2004-09-21 | 2007-01-19 | 주식회사종근당 | 파록세틴의 콜린산 또는 콜린산 유도체 염 |
CN104402708A (zh) * | 2014-12-07 | 2015-03-11 | 河南领先科技药业有限公司 | 一种樟脑酸钠的生产方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
EP0223403B1 (en) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
HU221921B1 (hu) * | 1996-07-08 | 2003-02-28 | Richter Gedeon Vegyészeti Gyár Rt. | N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására |
-
1998
- 1998-04-25 GB GBGB9808894.1A patent/GB9808894D0/en not_active Ceased
-
1999
- 1999-04-23 JP JP2000545859A patent/JP2002513020A/ja active Pending
- 1999-04-23 BR BR9909878-4A patent/BR9909878A/pt not_active Application Discontinuation
- 1999-04-23 AP APAP/P/2000/001958A patent/AP2000001958A0/en unknown
- 1999-04-23 PL PL99343596A patent/PL343596A1/xx not_active Application Discontinuation
- 1999-04-23 HU HU0102298A patent/HUP0102298A2/hu unknown
- 1999-04-23 SK SK1590-2000A patent/SK15902000A3/sk unknown
- 1999-04-23 KR KR1020007011750A patent/KR20010042929A/ko not_active Application Discontinuation
- 1999-04-23 WO PCT/GB1999/001246 patent/WO1999055699A1/en not_active Application Discontinuation
- 1999-04-23 IL IL13901899A patent/IL139018A0/xx unknown
- 1999-04-23 EA EA200001105A patent/EA200001105A1/ru unknown
- 1999-04-23 TR TR2000/03083T patent/TR200003083T2/xx unknown
- 1999-04-23 AU AU36186/99A patent/AU3618699A/en not_active Abandoned
- 1999-04-23 CN CN99807798A patent/CN1306530A/zh active Pending
- 1999-04-23 CA CA002329913A patent/CA2329913A1/en not_active Abandoned
- 1999-04-23 EP EP99918153A patent/EP1076659A1/en not_active Withdrawn
-
2000
- 2000-10-24 NO NO20005351A patent/NO20005351L/no not_active Application Discontinuation
- 2000-11-21 BG BG104973A patent/BG104973A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
BG104973A (bg) | 2001-09-28 |
TR200003083T2 (tr) | 2001-02-21 |
WO1999055699A1 (en) | 1999-11-04 |
PL343596A1 (en) | 2001-08-27 |
IL139018A0 (en) | 2001-11-25 |
NO20005351D0 (no) | 2000-10-24 |
EA200001105A1 (ru) | 2001-04-23 |
JP2002513020A (ja) | 2002-05-08 |
BR9909878A (pt) | 2000-12-26 |
HUP0102298A2 (hu) | 2002-05-29 |
CN1306530A (zh) | 2001-08-01 |
AP2000001958A0 (en) | 2000-12-31 |
NO20005351L (no) | 2000-10-24 |
EP1076659A1 (en) | 2001-02-21 |
GB9808894D0 (en) | 1998-06-24 |
AU3618699A (en) | 1999-11-16 |
KR20010042929A (ko) | 2001-05-25 |
SK15902000A3 (sk) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1414454A1 (en) | Paroxetine glycyrrhizinate | |
GB2367003A (en) | Paroxetine methansulphonate compositions | |
CA2319652A1 (en) | Salts of paroxetine | |
EP1137636A1 (en) | Process for preparation of paroxetine maleate | |
CA2327450A1 (en) | Paroxetine maleate | |
CA2330055A1 (en) | Paroxetine ascorbate | |
CA2329913A1 (en) | Paroxetine 10-camphorsulfonate for treatment of cns disorders | |
MXPA00010435A (en) | Paroxetine 10-camphorsulfonate for treatment of cns disorders | |
MXPA00010439A (en) | Paroxetine ascorbate | |
US20040143120A1 (en) | Paroxetine maleate | |
AU2528899A (en) | Salts of paroxetine | |
MXPA00009884A (en) | Paroxetine maleate | |
CZ20003942A3 (cs) | Askorbat paroxetinu | |
EP1408039A2 (en) | Mixed paraxetine propan-2-ol solvates | |
WO2001014369A2 (en) | Process for the preparation of paroxetin.hcl | |
MXPA00007719A (en) | Salts of paroxetine | |
WO2001025201A1 (en) | Process for the preparation of paroxetin intermediate | |
CZ20003941A3 (cs) | 10-KafrsuIfonat paroxetinu pro léčbu poruch centrálního nervového systému | |
WO2001025230A1 (en) | Process for the preparation of paroxetine hydrochloride acetone solvate | |
CZ20003722A3 (cs) | Maleat paroxetinu | |
WO2001012623A1 (en) | Process for the preparation of paroxetine hydrochloride | |
WO2000032596A1 (en) | Amine salts of paroxetine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |